Neoadjuvant chemotherapy in women with invasive breast carcinoma: Conceptual basis and fundamental surgical issues

Journal of the American College of Surgeons

Volumn 190, Issue 3, 2000, Pages 350-363

  Kuerer, Henry M ^a   Hunt, Kelly K ^a   Newman, Lisa A ^a   Ross, Merrick I ^a   Ames, Frederick C ^a   Singletary, Sonja E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ADJUVANT CHEMOTHERAPY; AXILLA; BREAST CARCINOMA; BREAST RECONSTRUCTION; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; HUMAN; LYMPH NODE BIOPSY; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

BIOPSY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODES; MAGNETIC RESONANCE IMAGING; MASTECTOMY, MODIFIED RADICAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034003561     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(99)00272-0     Document Type: Review

References (87)

1. Haagensen CD, Stout A. Carcinoma of the breast. II. Criteria of operability. Ann Surg 1943;118:859.
2. Hunt KK, Ames FC, Singletary SE, et al. Locally advanced non-inflammatory breast cancer. Surg Clin North Am 1996;76:393-410.
3. Rubens RD, Armitage P, Winter PJ, et al. Prognosis in inoperable stage III carcinoma of the breast. Eur J Cancer 1977;13:805-811.
4. Fracchia AA, Evans JF, Eisenberg BL. Stage III carcinoma of the breast. A detailed analysis. Ann Surg 1980;192:705-710.
5. Arnold DJ, Lesnick GJ. Survival following mastectomy for stage III breast cancer. Am J Surg 1979;137:362-366.
6. Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988;62:2507-2516.
7. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-187.
8. Koscielny S, Tubiana M, Le MG, et al. Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 1984;49:709-715.
9. Bonadonna G, Valagussa P, Zucali R, et al. Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin 1995;45:227-243.
10. Jacquillat C, Weil M, Baillet F, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990;66:119-129.
11. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998;16:93-100.
12. Kuerer HM, Newman LA, Fornage BD, et al. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol 1998;5:673-680.
13. Abraham DC, Jones RC, Jones SE, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 1996;78:91-100.
14. Esserman L, Hylton N, Yassa L, et al. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 1999;17:110-119.
15. Ciarmiello A, Del Vecchio S, Silvestro P, et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998;16:1677-1683.
16. Flanagan FL, Dehdashti F, Siegel BA. PET in breast cancer. Semin Nucl Med 1998;28:290-302.
17. McCready DR, Hortobagyi GN, Kau SW, et al. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 1989;124: 21-25.
18. Touboul E, Lefranc JP, Blondon J, et al. Multidisciplinary treatment approach to locally advanced non-inflammatory breast cancer using chemotherapy and radiotherapy with or without surgery. Radiother Oncol 1992;25:167-175.
19. Kuerer HM, Newman LA, Buzdar AU, et al. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status [sec comments]. Cancer J Sci Am 1998;4:230-236.
20. Newman LA, Kuerer HM, Hunt KK, et al. Response to induction chemotherapy in black and white patients with locally advanced breast cancer. Breast Cancer Res Treat 1998;50:242 [abstract].
21. Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999;10:47-52.
22. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overwire of the randomised trials. Lancet 1998;352:930-942.
23. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339:1-15.
24. Delena M, Zucali R, Viganotti G, et al. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978;1:53-59.
25. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493.
26. Hortobagyi GN, Blumenschein GR, Spanos W, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983;51:763-768.
27. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-469.
28. Lippman ME, Sorace RA, Bagley CS, et al. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. NCI Monogr 1986;1:153-159.
29. Mamounas EP. NSABP protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. Oncology (Huntingt) 1997;11:37-40.
30. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994;5: 645-652.
31. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995;13:547-552.
32. Cunningham JD, Weiss SE, Ahmed S, et al. The efficacy of neoadjuvant chemotherapy compared to postoperative therapy in the treatment of locally advanced breast cancer. Cancer Invest 1998;16:80-86.
33. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685.
34. Fisher B, Saffer E, Rudock C, et al. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res 1989;49:2002-2004.
35. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88: 277-285.
36. Remvikos Y, Jouve M, Beuzeboc P, et al. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer 1993;13: 1843-1848.
37. Chevillard S, Pouillart P, Beldjord C, et al. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 1996;77:292-300.
38. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990;82:1539-1545.
39. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90: 1361-1370.
40. Willsher PC, Pinder SE, Gee JM, et al. C-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer. Anticancer Res 1998;18:3695-3698.
41. Makris A, Powles TJ, Dowsett M, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997;3:593-600.
42. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
43. Makris A, Powles TJ, Kakolyris S, et al. Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer 1999;85:1996-2000.
44. Bougnoux P, Germain E, Chajes V, et al. Cytotoxic drugs efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma. Br J Cancer 1999;79:1765-1769.
45. Schwartz GF, Birchansky CA, Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994;73:362-369.
46. Valero V, Hortobagyi GN. Primary chemotherapy: a better overall therapeutic option for patients with breast cancer [editorial]. Ann Oncol 1998;9:1151-1154.
47. Buzdar AU, Hortobagyi GN, Asmar L, et al. Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/ doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer. Semin Oncol 1997;24 [Suppl 17]: S17-31-S17-34.
48. Mamounas EP. Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies. Semin Oncol 1998; 25:31-35.
49. Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 1998;176:502-509.
50. Veronesi U, Bonadonna G, Zurrida S, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 1995;222:612-618.
51. Margolese RG. Surgical considerations in preoperative chemotherapy of breast cancer. Recent Results Cancer Res 1998;152: 193-201.
52. Lawrence WT, Talbot TL, Norton JA. Preoperative or postoperative doxorubicin hydrochloride (Adriamycin): which is better for wound healing? Surgery 1986;100:9-13.
53. Broadwater JR, Edwards MJ, Kuglen C, et al. Mastectomy following preoperative chemotherapy. Strict operative criteria control operative morbidity. Ann Surg 1991;213:126-129.
54. Danforth DN Jr, Lippman ME, McDonald H, et al. Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer. Am Surg 1990;56:6-11.
55. Forastiere AA, Urba SG, Liggett W. Neoadjuvant therapy. Cancer J Sci Am 1996;2:126-131.
56. Danforth DN Jr, Zujewski J, O'Shaughnessy J, et al. Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA, B breast cancer. Ann Surg Oncol 1998;5:150-158.
57. Ellis P, Smith I, Ashley S, et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 1998;16:107-114.
58. Balch CM, Singletary SE, Bland KI. Clinical decision-making in early breast cancer. Ann Surg 1993;217:207-225.
59. Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995; 333:1456-1461.
60. Veronesi U, Luini A, Del Vecchio M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med 1993;328:1587-1591.
61. Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 1994;74:416-423.
62. Singletary SE, McNeese MD, Hortobagyi GN. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 1992;69:2849-2852.
63. Singletary SE, Dhingra K, Yu DH. New strategies in locally advanced breast cancer. Cancer Treat Res 1997;90:253-271.
64. Calais G, Berger C, Descamps P, et al. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 1994;74:1283-1288.
65. Touboul E, Lefranc JP, Blondon J, et al. Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced non-inflammatory breast cancer. Radiother Oncol 1997;42:219-229.
66. Merajver SD, Weber BL, Cody R, et al. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. J Clin Oncol 1997;15: 2873-2881.
67. Makris A, Powles TJ, Ashley SE, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998;9:1179-1184.
68. Fisher B, Mamounas EP. Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer [editorial]. J Clin Oncol 1995;13:537-540.
69. Peoples GE, Quan R, Heaton KM, et al. Breast conservation therapy for large and locally advanced breast cancers after induction chemotherapy. Ann Surg Oncol (in press).
70. Hunt KK, Buzdar AU. Breast conservation and tumor down-staging. In: Singletary S, ed. Breast cancer. New York: Springer-Verlag; 1998:196-205.
71. Klimberg VS, Westbrook KC, Korourian S. Use of touch preps for diagnosis and evaluation of surgical margins in breast cancer. Ann Surg Oncol 1998;5:220-226.
72. Curley SA, Davidson BS, Fleming RY, et al. Laparoscopically guided bipolar radiofrequency ablation of areas of porcine liver. Surg Endosc 1997;11:729-733.
73. Staren ED, Sabel MS, Gianakakis LM, et al. Cryosurgery of breast cancer. Arch Surg 1997;132:28-34.
74. Robinson DS, Parel JM, Denham DB, et al. Interstitial laser hyperthermia model development for minimally invasive therapy of breast carcinoma. J Am Coll Surg 1998;186:284-292.
75. Fisher B, Slack NH, Bross ID. Cancer of the breast: size of neoplasm and prognosis. Cancer 1969;24:1071-1080.
76. Fisher B, Wolmark N, Bauer M, et al. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981;152:765-772.
77. Kuerer HM, Sahin A, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases prior to surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999;230:72-78.
78. Cox CE, Haddad F, Bass S, et al. Lymphatic mapping in the treatment of breast cancer. Oncology (Huntingt) 1998;12: 1283-1298.
79. Newman LA, Kuerer HM, Hunt KK, et al. Feasibility of immediate breast reconstruction for locally advanced breast cancer. Ann Surg Oncol 1999;6:671-675.
80. Hunt KK, Baldwin BJ, Strom EA, et al. Feasibility of postmastectomy radiation therapy after TRAM flap breast reconstruction. Ann Surg Oncol 1997;4:377-384.
81. McMasters KM, Hunt KK. Neoadjuvant chemotherapy, locally advanced breast cancer, and quality of life [editorial]. J Clin Oncol 1999;17:441-444.
82. Styblo TM, Lewis MM, Carlson GW, et al. Immediate breast reconstruction for stage III breast cancer using transverse rectus abdominis musculocutaneous (TRAM) flap. Ann Surg Oncol 1996;3:375-380.
83. Sultan MR, Smith ML, Estabrook A, et al. Immediate breast reconstruction in patients with locally advanced disease. Ann Plast Surg 1997;38:345-351.
84. Brain E, Garrino C, Misset JL, et al. Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. Br J Cancer 1997;75:1360-1367.
85. Valagussa P, Zambetti M, Bonadonna G, et al. Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy. Breast Cancer Res Treat 1990;15:137-147.
86. Morrell LE, Lee YJ, Hurley J, et al. A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. Cancer 1998;82:503-511.
87. Fisher B. Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer. CA Cancer J Clin 1999;49:159-177.